Lv5
982 积分 2022-03-14 加入
Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities
10天前
已完结
Resistance Mechanisms to Anti-PD Cancer Immunotherapy
10天前
已完结
Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients
10天前
已完结
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
10天前
已完结
Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies
10天前
已完结
Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies
14天前
已完结
Association Between Duration of Immunotherapy and Overall Survival in Advanced Non–Small Cell Lung Cancer
23天前
已完结
Serplulimab With Chemotherapy in Extensive-Stage SCLC
1个月前
已完结
Rationale and Design of a Phase II Trial of Combined Serplulimab and Chemotherapy in Patients with Histologically Transformed SCLC: a Prospective, Single-Arm and Multicenter Study
1个月前
已完结
Re-inventing a better wheel? Serplulimab for squamous cell lung cancer
1个月前
已完结
皖公网安备34019202002308
